409 related articles for article (PubMed ID: 20418202)
1. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
[TBL] [Abstract][Full Text] [Related]
2. [Angiogenesis targeting in renal carcinomas].
Pouessel D; Culine S
Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ; Bukowski RM
J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
[TBL] [Abstract][Full Text] [Related]
5. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
7. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
8. [Effect of angiogenesis inhibitors on renal cell carcinoma].
Bodrogi I
Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
[TBL] [Abstract][Full Text] [Related]
9. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
Mills EJ; Rachlis B; O'Regan C; Thabane L; Perri D
BMC Cancer; 2009 Jan; 9():34. PubMed ID: 19173737
[TBL] [Abstract][Full Text] [Related]
10. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract][Full Text] [Related]
11. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
12. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
de Mulder PH; Haanen JB; Sleijfer S; Kruit WH; Gietema JA; Richel DJ; Groenewegen G; Voest EE; van den Eertwegh AJ; Osanto S; Jansen RL; Mulders PF
Ned Tijdschr Geneeskd; 2008 Feb; 152(7):371-5. PubMed ID: 18380383
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
Chowdhury S; Larkin JM; Gore ME
Eur J Cancer; 2008 Oct; 44(15):2152-61. PubMed ID: 18829302
[TBL] [Abstract][Full Text] [Related]
14. [The role of angiogenesis in renal carcinoma].
Bussolati B; Satolli MA; Camussi G
G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
[TBL] [Abstract][Full Text] [Related]
15. [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
Sire M; Wallerand H; Kilkoski F; Grenier N; Ferrière JM; Ravaud A
Bull Cancer; 2008 Sep; 95(9):813-20. PubMed ID: 18829413
[TBL] [Abstract][Full Text] [Related]
16. [Renal cell carcinoma and antiangiogenic therapies].
Pouessel D; Culine S; Verhoest G; Patard JJ
Presse Med; 2008 Apr; 37(4 Pt 2):628-33. PubMed ID: 18035517
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
Hutson TE
Oncologist; 2011; 16 Suppl 2(Suppl 2):14-22. PubMed ID: 21346036
[TBL] [Abstract][Full Text] [Related]
18. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
19. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
[TBL] [Abstract][Full Text] [Related]
20. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
Fléchon A; Boyle H; Négrier S
Bull Cancer; 2010; 97():73-82. PubMed ID: 20418206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
